Document Detail


Pathologically activated therapeutics for neuroprotection.
MedLine Citation:
PMID:  17882256     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Many drugs that have been developed to treat neurodegenerative diseases fail to gain approval for clinical use because they are not well tolerated in humans. In this article, I describe a series of strategies for the development of neuroprotective therapeutics that are both effective and well tolerated. These strategies are based on the principle that drugs should be activated by the pathological state that they are intended to inhibit. This approach has already met with success, and has led to the development of the potentially neuroprotective drug memantine, an N-methyl-D-aspartate (NMDA)-type and glutamate receptor antagonist.
Authors:
Stuart A Lipton
Related Documents :
8056996 - Mechanisms of the development of trazodone withdrawal symptoms.
24681196 - Serotonergic modulation of zebrafish behavior: towards a paradox.
24903146 - Baicalein-nicotinamide cocrystal with enhanced solubility, dissolution, and oral bioava...
24306626 - Use of drugs among senegalese school going adolescents.
21053156 - Nonclinical and clinical experiences with cpp-based self-assembling peptide systems in ...
15237856 - Clinical perspectives on xenobiotic-induced hepatotoxicity.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Nature reviews. Neuroscience     Volume:  8     ISSN:  1471-0048     ISO Abbreviation:  Nat. Rev. Neurosci.     Publication Date:  2007 Oct 
Date Detail:
Created Date:  2007-09-20     Completed Date:  2007-10-16     Revised Date:  2007-11-19    
Medline Journal Info:
Nlm Unique ID:  100962781     Medline TA:  Nat Rev Neurosci     Country:  England    
Other Details:
Languages:  eng     Pagination:  803-8     Citation Subset:  IM    
Affiliation:
Burnham Institute for Medical Research, The Salk Institute for Biological Studies, The Scripps Research Institute, and the University of California at San Diego 10901 North Torrey Pines Road, La Jolla, California 29,037, USA. slipton@burnham.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Drug Delivery Systems / methods*
Excitatory Amino Acid Antagonists / metabolism,  therapeutic use
Humans
Memantine / metabolism,  therapeutic use
Neurodegenerative Diseases / drug therapy,  metabolism,  prevention & control*
Neuroprotective Agents / metabolism*,  therapeutic use
Receptors, N-Methyl-D-Aspartate / agonists,  antagonists & inhibitors,  metabolism
Chemical
Reg. No./Substance:
0/Excitatory Amino Acid Antagonists; 0/Neuroprotective Agents; 0/Receptors, N-Methyl-D-Aspartate; 19982-08-2/Memantine
Comments/Corrections
Erratum In:
Nat Rev Neurosci. 2007 Nov;8(11):2p following 903

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Neurons and networks in daily rhythms.
Next Document:  Noncoding transcription controls downstream promoters to regulate T-cell receptor alpha recombinatio...